Drug Profile
INO 8000
Alternative Names: GLS-6150; Hepatitis C vaccine - Inovio/VGX; INO-8000; VGX-6150Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator University of Pennsylvania
- Developer GeneOne Life Science; Inovio Pharmaceuticals; Mayo Clinic
- Class DNA vaccines; Hepatitis C vaccines
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Hepatitis C
Most Recent Events
- 06 Sep 2023 Phase I development for Hepatitis-C (Prevention, Treatment-experienced) is ongoing in South Korea (Intradermal) (GeneOne Life Science pipeline, September 2023)
- 06 Sep 2023 Phase- I for development for Hepatitis-C is ongoing in the US and Puerto Rico (IM) (GeneOne Life Science pipeline, September 2023)
- 28 Oct 2021 No recent reports of development identified for phase-I development in Hepatitis-C(Prevention, Treatment-experienced) in South Korea (Intradermal, Injection)